{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:06:59Z","timestamp":1787893619667,"version":"build-2784847793"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":42,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The clinical characteristics and treatment outcomes in patients with eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) have not been extensively investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We determined treatment outcomes and frequencies of disease-related complications in patients with EoE and IBD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 69 patients who met inclusion criteria, 39 (56.5%) had a diagnosis of Crohn disease. Clinical and histologic response rates to proton pump inhibitors and topical steroids were 25.9% and 24.4%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Lower than expected clinical and histologic response rates for EoE suggest the combination of EoE and IBD is a medically refractory phenotype with more difficult to treat EoE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otab018","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T20:28:51Z","timestamp":1614803331000},"source":"Crossref","is-referenced-by-count":7,"title":["The Clinical Characteristics and Treatment Outcomes of Concomitant Eosinophilic Esophagitis and Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-0480","authenticated-orcid":false,"given":"Siri A","family":"Urquhart","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Mayo Clinic , Rochester, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P","family":"Quinn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ravi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"key":"2022111812293539100_CIT0001","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/j.jaci.2009.11.037","article-title":"Mucosal immunology, eosinophilic esophagitis, and other intestinal inflammatory diseases","volume":"125","author":"Atkins","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"2022111812293539100_CIT0002","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000497236","article-title":"Increased prevalence of esophageal eosinophilia in patients with inflammatory bowel disease","volume":"3","author":"Fan","year":"2019","journal-title":"Inflamm Intest Dis."},{"key":"2022111812293539100_CIT0003","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/2050640616672953","article-title":"Eosinophilic esophagitis: what can we learn from Crohn\u2019s disease?","volume":"5","author":"Molina-Infante","year":"2017","journal-title":"United European Gastroenterol J."},{"key":"2022111812293539100_CIT0004","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/gutjnl-2018-318074","article-title":"Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis","volume":"68","author":"Limketkai","year":"2019","journal-title":"Gut."},{"key":"2022111812293539100_CIT0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fmed.2017.00261","article-title":"Eosinophilic gastrointestinal disorders pathology","volume":"4","author":"Collins","year":"2017","journal-title":"Front Med (Lausanne)."},{"key":"2022111812293539100_CIT0006","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.crohns.2011.02.009","article-title":"Eosinophilic-Crohn overlap colitis and review of the literature","volume":"5","author":"Katsanos","year":"2011","journal-title":"J Crohns Colitis."},{"key":"2022111812293539100_CIT0007","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet."},{"key":"2022111812293539100_CIT0008","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bpg.2015.06.010","article-title":"Disease associations in eosinophilic oesophagitis and oesophageal eosinophilia","volume":"29","author":"Lucendo","year":"2015","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"2022111812293539100_CIT0009","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ajg.2013.71","article-title":"ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)","volume":"108","author":"Dellon","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2022111812293539100_CIT0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.iac.2015.04.003","article-title":"Eosinophils in gastrointestinal disorders: eosinophilic gastrointestinal diseases, celiac disease, inflammatory bowel diseases, and parasitic infections","volume":"35","author":"Mehta","year":"2015","journal-title":"Immunol Allergy Clin North Am."},{"key":"2022111812293539100_CIT0011","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/ajg.2017.402","article-title":"Peripheral eosinophilia in patients with inflammatory bowel disease defines an aggressive disease phenotype","volume":"112","author":"Click","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"2022111812293539100_CIT0012","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/ajg.2012.443","article-title":"Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia","volume":"108","author":"Moawad","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2022111812293539100_CIT0013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","article-title":"Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis","volume":"14","author":"Lucendo","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022111812293539100_CIT0014","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s10620-009-0859-4","article-title":"Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis","volume":"55","author":"Peterson","year":"2010","journal-title":"Dig Dis Sci."},{"key":"2022111812293539100_CIT0015","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/apt.12513","article-title":"The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor","volume":"38","author":"Vazquez-Elizondo","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"2022111812293539100_CIT0016","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology."},{"key":"2022111812293539100_CIT0017","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.cgh.2012.03.018","article-title":"Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis","volume":"10","author":"Alexander","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022111812293539100_CIT0018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cgh.2014.05.021","article-title":"Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis","volume":"13","author":"Gupta","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022111812293539100_CIT0019","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2010.07.048","article-title":"Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis","volume":"139","author":"Straumann","year":"2010","journal-title":"Gastroenterology."},{"key":"2022111812293539100_CIT0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","article-title":"Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis","volume":"143","author":"Dellon","year":"2012","journal-title":"Gastroenterology."},{"key":"2022111812293539100_CIT0021","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.gastro.2016.11.021","article-title":"Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis","volume":"152","author":"Dellon","year":"2017","journal-title":"Gastroenterology."},{"key":"2022111812293539100_CIT0022","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jgh.13281","article-title":"Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials","volume":"31","author":"Murali","year":"2016","journal-title":"J Gastroenterol Hepatol."},{"key":"2022111812293539100_CIT0023","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.14309\/01.ajg.0000591040.97478.4c","article-title":"Histologic response to steroids in eosinophilic esophagitis is dependent on dose and delivery compound","volume":"114","author":"Schupack","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"2022111812293539100_CIT0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.giec.2017.07.003","article-title":"Endoscopic and radiologic findings in eosinophilic esophagitis","volume":"28","author":"Alexander","year":"2018","journal-title":"Gastrointest Endosc Clin N Am."},{"key":"2022111812293539100_CIT0025","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1097\/MIB.0000000000000469","article-title":"Crohn\u2019s disease of the esophagus: clinical features and treatment outcomes in the biologic era","volume":"21","author":"De Felice","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812293539100_CIT0026","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cgh.2011.12.042","article-title":"Esophageal diameter is decreased in some patients with eosinophilic esophagitis and might increase with topical corticosteroid therapy","volume":"10","author":"Lee","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022111812293539100_CIT0027","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.gtc.2017.05.003","article-title":"Epidemiology, natural history, and risk stratification of Crohn\u2019s disease","volume":"46","author":"Aniwan","year":"2017","journal-title":"Gastroenterol Clin North Am."},{"key":"2022111812293539100_CIT0028","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology."},{"key":"2022111812293539100_CIT0029","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.crohns.2013.09.009","article-title":"A tale of two diseases: the history of inflammatory bowel disease","volume":"8","author":"Mulder","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2022111812293539100_CIT0030","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.06.022","article-title":"The potential role of vedolizumab in concomitant eosinophilic esophagitis and Crohn\u2019s disease","volume":"16","author":"Taft","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022111812293539100_CIT0031","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2008.06.012","article-title":"Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis","volume":"122","author":"Straumann","year":"2008","journal-title":"J Allergy Clin Immunol."},{"key":"2022111812293539100_CIT0032","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/gut.37.2.242","article-title":"Activated eosinophils and interleukin 5 expression in early recurrence of Crohn\u2019s disease","volume":"37","author":"Dubucquoi","year":"1995","journal-title":"Gut."},{"key":"2022111812293539100_CIT0033","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1067\/mai.2001.119917","article-title":"Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response","volume":"108","author":"Straumann","year":"2001","journal-title":"J Allergy Clin Immunol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otab018\/37929543\/otab018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/3\/2\/otab018\/47118193\/otab018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/3\/2\/otab018\/47118193\/otab018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T12:30:38Z","timestamp":1668774638000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otab018\/6274996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otab018","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,4,1]]},"article-number":"otab018"}}